Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

SummaryBackground Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity, but the effects of this drug on outcomes in patients with atherosclerotic cardiovascular disease and heart failure are unknown. We report a prespecified analysis of the effect of once-weekly subcutaneous semaglutide 2·4 mg on ischaemic and heart failure cardiovascular outcomes. We aimed to investigate if semaglutide was beneficial in patients with atherosclerotic cardiovascular disease with a history of heart failure compared with placebo; if there was a difference in outcome in patients designated as having heart failure with preserved ejection fraction…

• A
  Amgen
• BS
  Bristol-Myers Squibb
• EL
  Eli Lilly and Company
• P
  Pfizer
• A
  AstraZeneca
• G
  GlaxoSmithKline
• S
  Sanofi
• BA
  Brigham and Women's Hospital
• AP
  Alnylam Pharmaceuticals
• F
  FibroGen
• CB
  CSL Behring
• RP
  Regeneron Pharmaceuticals
• TT
  TG Therapeutics
• N
  Novavax
• IT
  Intarcia Therapeutics
• AC
  Amarin Corporation
• MC
  MannKind Corporation
• RM
  ReCor Medical
• M
  Mylan
• B
  BeiGene
• M
  Moderna
• I
  Insmed
• DU
  Diabetes UK
• EC
  European Commission
• NN
  Novo Nordisk
• S
  Shionogi
• S
  Servier
• HL
  H. Lundbeck A/S
• I
  Ipsen
• AT
  Akebia Therapeutics
• ET
  Esperion Therapeutics
• A
  Allergan
• MR
  Medical Research Council

  Award: MR/T018186/1
• DS
  Daiichi Sankyo Europe